AUTHOR INDEX

(P = Proceedings, S = Supplement)

AARONS, L. *see* CALLIES, S.
ABDUL-MANAP, R. *see* MOGHADAMNIA, A.A.
ADITHAN, C., GERARD, N., VASU, S., ROSEMARY, J., SHASHINDRAN, C.H. & KRISHNAMOORTHY, R. Allele and genotype frequency of *CYP2C19* in a Tamilian population: 331
AFFRIME, M. *see* GUPTA, S.K.
ALJAZAF, K., HALE, T.W., ILETT, K.F., HARTMANN, P.E., MITOULAS, L.R., KRISTENSEN, J.H. & HACKETT, L.P. Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk: 18
ALLABI, A.C., GALA, J.-L., DESAGER, J.-P., HEUSTERSPREUTE, M. & HORSMANS, Y. Genetic polymorphisms of *CYP2C9* and *CYP2C19* in the Beninese and Belgian populations: 653
ALLORGE, D., CHEVALIER, D., LO-GUIDICE, J.-M., CAUFFIEZ, C., SUARD, F., BAUMANN, P., EAP, C.B. & BROLY, F. Identification of a novel splice-site mutation in the CYP1A2 gene: 341
AL-SHURBAJI, A. *see* ANNAS, A.
ALVÁN, G. *see* ANNAS, A.
ANNAS, A., CARLSTRÖM, K., ALVÁN, G. & AL-SHURBAJI, A. The effect of ketoconazole and diltiazem on oestrogen metabolism in postmenopausal women after single dose oestradiol treatment: 334
Announcement: 698
ANTMAN, E.M. *see* BRUNO, R.
ANTTILA, M., PENTTILÄ, J., HELMINEN, A., VUORILEHTO, L. & SCHEININ, H. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects: 691
ARAI, H. *see* OHNUMA, T.
ARLET-SUAU, E. *see* ASTUDILLO, L.
ARONSON, J.K. Features of this month's *Journal*: 1, 141, 247, 347, 475
ARONSON, J.K. Nurse prescribers & reporters: 585
ASHWOOD, T. *see* ZINGMARK, P.-H.
ASTUDILLO, L., GUILLARD, O., SAILLER, L., RIGAL, F., COURET, B. & ARLET-SUAU, E. Lead poisoning by self-administration in an exposed worker: 695
AUTON, T.R. *see* DOWNHAM, M.R.

BABER, N. & PRITCHARD, D. Dose estimation for children: 489
BABER, N. *see* MUCKLOW, J.
BACKMAN, J.T. *see* NIEMI, M.
BAILLE, P. *see* BRUNO, R.
BALRAM, C., SHARMA, A., SIVATHASAN, C. & LEE, E.J.D. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic–genotypic correlates: 78
BARNES, T.R.E. *see* FLANAGAN, R.J.
BATEMAN, D.N. *see* CAMIDGE, D.R.
BATEMAN, D.N. *see* LANGFORD, N.J.
BAUMANN, P. *see* ALLORGE, D.
BECKER, R. *see* BRUNO, R.
BEIJNEN, J.H. *see* CALLIES, S.
BELLDINA, E.B., HUANG, M.Y., SCHNEIDER, J.A., BRUNDAGE, R.C. & TRACY, T.S. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients: 520
BELLE, D. *see* GUPTA, S.K.
BELZ, G.G. Angiotensin II dose–effect curves and Schild regression plots for characterization of different angiotensin II AT_1 receptor antagonists in clinical pharmacology: 3
BENNETT, T. *see* DOWNHAM, M.R.
BENÖHR, P. *see* FREUDENTHALER, S.
BERGSTROM, R.F. *see* SATHIRAKUL, K.
BERTILSSON, L. *see* HÄRTTER, S.
BERTILSSON, L. *see* HELLMAN, K.
BERTILSSON, L. *see* HERRLIN, K.
BIDSTRUP, T.B., BJORNSDOTTIR, I., SIDELMANN, U.G., THOMSEN, M.S. & HANSEN, K.T. CYP2C8 and CYP3A4 are the principal enzymes involved in the human *in vitro* biotransformation of the insulin secretagogue repaglinide: 305
BITZER, J. *see* PFRUNDER, A.
BJORNSDOTTIR, I. *see* BIDSTRUP, T.B.
BJARNASON, I. *see* SMALE, S.
BOOS, J. *see* HEMPEL, G.
BOURIN, M. *see* DAILLY, E.
BOYLE, J. *see* WILSON, Z.E.
BRADBURY, B.D. *see* KAYE, J.A.
BRADY, A. *see* PATTERSON, D.
BREDDIN, H.K. *see* GRAFF, J.
BRIEN, S., LEWITH, G. & BRYANT, T. Ultramolecular homeopathy has no observable clinical effects. A randomized, double-blind, placebo-controlled proving trial of Belladonna 30C: 562
BROADHURST, C., WILSON, K.C.M., KINIRONS, M.T., WAGG, A. & DHESI, J.K. Clinical pharmacology of old age syndromes: 261
BROLY, F. *see* ALLORGE, D.
BRUNDAGE, R.C. *see* BELLDINA, E.B.
BRUNO, R., BAILLE, P., RETOUT, S., VIVIER, N., VEYRAT-FOLLET, C., SANDERINK, G.-J., BECKER, R. & ANTMAN, E.M. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction: 407
BRYANT, T. *see* BRIEN, S.
BURGESS, M. *see* CALLIES, S.
BURHENNE, J. *see* RENGELSHAUSEN, J.
BURN, J.L. *see* WILSON, Z.E.

CAI, W.-M. *see* YAN, F.-X.
CALLIES, S., DE ALWIS, D.P., HARRIS, A., VASEY, P., BEIJNEN, J.H., SCHELLENS, J.H., BURGESS, M. & AARONS, L. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979): 46
CAMIDGE, D.R., WOOD, R.J. & BATEMAN, D.N. The epidemiology of self-poisoning in the UK: 613
CARBONARA, O. *see* SASSO, F.C.
CARLSTRÖM, K. *see* ANNAS, A.
CARTY, E. & RAMPTON, D.S. Evaluation of new therapies for inflammatory bowel disease: 351
CAUFFIEZ, C. *see* ALLORGE, D.
CAZALI, N., TRAN, A., TRELUYER, J.M., REY, E., D'ATHIS, P., VINCENT, J. & PONS, G. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human: 526
CHAN, C. *see* SATHIRAKUL, K.
CHAN, T.M. *see* KUMANA, C.R.
CHEVALIER, D. *see* ALLORGE, D.
CHOWDRY, J. *see* SHIRAN, M.R.
CHRYSTYN, H. *see* TOMLINSON, H.S.
COCKBURN, W.J. *see* LEE, D.K.C.
COCKBURN, W.J.R. *see* CURRIE, G.P.
COHEN, E. *see* SHARABI, A.
COPPOLA, L. *see* SASSO, F.C.
CORLETT, S.A. *see* TOMLINSON, H.S.
COURET, B. *see* ASTUDILLO, L.
CREUTZIG, U. *see* HEMPEL, G.
CUMMINGS, M.H. *see* FAYERS, K.E.

CURRIE, G.P. *see* LEE, D.K.C.
CURRIE, G.P., LIMA, J.J., SYLVESTER, J.E., LEE, D.K.C., COCKBURN, W.J.R. & LIPWORTH, B.J. Leukotriene C_4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma: 422
CURRIE, G.P., STENBACK, S. & LIPWORTH, B.J. Effects of fluticasone *vs.* fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma: 11

D'ATHIS, P. *see* CAZALI, N.
DAHLEM, P. *see* DUIJVESTIJN, Y.C.M.
DAILLY, E., PANNIER, M., JOLLIET, P. & BOURIN, M. Population pharmacokinetics of ceftazidime in burn patients: 629
DARIMONT, J. *see* SKARKE, C.
DAVIES, D.P. *see* SRI RANGANATHAN, S.
DAWIDOWICZ, A.L., KALITYŃSKI, R. & FIJALKOWSKA, A. Free and bound propofol concentrations in human cerebrospinal fluid: 545
DAWSON, A.H. *see* ISBISTER, G.K.
DAY, R.O. *see* SASONGKO, L.
DE ALWIS, D.P. *see* CALLIES, S.
DE GLANVILLE, H. & FERNER, R. David Margerison Davies, 1923–2002: 139
DE GRAAF, L. & DIEMONT, W.L. Chest pain during use of bupropion as an aid in smoking cessation: 451
DELANEY, C. *see* LIAO, W.-C.
DESAGER, J.-P. *see* ALLABI, A.C.
DHESI, J.K. *see* BROADHURST, C.
DICPINIGAITIS, P.V. & GAYLE, Y.E. Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function: 501
DIEMONT, W.L. *see* DE GRAAF, L.
DOLOVICH, M.B. *see* LABIRIS, N.R.
DOMSCHKE, W. *see* POHLE, T.
DOWNHAM, M.R., AUTON, T.R., ROSUL, A., SHARP, H.L., SJÖSTRÖM, L., RUSHTON, A., RICHARDS, J.P., MANT, T.G.K., GARDINER, S.M., BENNETT, T. & GLOVER, J.F. Evaluation of two carrier protein–angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man: 505
DREWE, J. *see* PFRUNDER, A.
DUFFULL, S.B. *see* GREEN, B.
DUFFULL, S.B. *see* SHUM, B.
DUIJVESTIJN, Y.C.M., KALMEIJER, M.D., PASSIER, A.L.M., DAHLEM, P. & SMIERS, F. Neonatal intraventricular haemorrhage associated with maternal use of paroxetine: 581

EAP, C.B. *see* ALLORGE, D.
EDWARDS, G. *see* OGUTU, B.R.
EDWARDS, G. *see* THOMSON, A.H.
EICHLERL, H.-G. *see* SYCHA, T.
EKBLOM, M. *see* ZINGMARK, P.-H.
EKINS-DAUKES, S., MCLAY, J.S., TAYLOR, M.W., SIMPSON, C.R. & HELMS, P.J. Antibiotic prescribing for children. Too much and too little? Retrospective observational study in primary care: 92
EL-ERAKY, H. & THOMAS, S.H.L. Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine: 198
ELLIS, S.W. *see* SHIRAN, M.R.
ELLIS, S.W. *see* WILSON, Z.E.
ENGLISH, M. *see* THOMSON, A.H.
Errata: 463, 584

FANTI, P. *see* YAN, F.-X.
FAYERS, K.E., CUMMINGS, M.H., SHAW, K.M. & LAIGHT, D.W. Nitrate tolerance and the links with endothelial dysfunction and oxidative stress: 620
FERNER, R. *see* DE GLANVILLE, H.
FERREIRA, I. *see* LIAO, W.-C.
FERRON, G.M., PATAT, A., PARKS, V., ROLAN, P. & TROY, S.M. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects: 39
FIJALKOWSKA, A. *see* DAWIDOWICZ, A.L.
FLANAGAN, R.J. & JONES, A.L. Antidotes: Principles and Clinical Applications: 458
FLANAGAN, R.J. The Forensic Pharmacology of Drugs of Abuse: 345
FLANAGAN, R.J., YUSUFI, B. & BARNES, T.R.E. Comparability of whole-blood and plasma clozapine and norclozapine concentrations: 135
FORD, N. *see* LIAO, W.-C.
FREDRIKSON, S. *see* HELLMAN, K.
FREUDENTHALER, S., BENÖHR, P., GRENZ, A., SELZER, T., SCHMIDT, T., MÖRIKE, K., OSSWALD, H. & GLEITER, C.H. Do alterations of endogenous angiotensin II levels regulate erythropoietin production in humans?: 378
FROSSARD, N. *see* PUROHIT, A.
FUJIMURA, A. *see* SUGIMOTO, K.-I.

GALA, J.-L. *see* ALLABI, A.C.
GARDINER, S.M. *see* DOWNHAM, M.R.
GARTY, M. *see* SHARABI, A.
GAYLE, Y.E. *see* DICPINIGAITIS, P.V.
GEISSLINGER, G. *see* SKARKE, C.
GERARD, N. *see* ADITHAN, C.
GERBER, S. *see* PFRUNDER, A.
GLEITER, C.H. *see* FREUDENTHALER, S.
GLOVER, J.F. *see* DOWNHAM, M.R.
GLUE, P. *see* GUPTA, S.K.
GÖGGELMANN, C. *see* RENGELSHAUSEN, J.
GODDARD, A.F. & LOGAN, R.P.H. Diagnostic methods for *Helicobacter pylori* detection and eradication: 273
GOOD, A.M. *see* LANGFORD, N.J.
GRAFF, J., KLINKHARDT, U., WESTRUP, D., KIRCHMAIER, C.M., BREDDIN, H.K. & HARDER, S. Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans: 321
GREEN, B. & DUFFULL, S.B. Development of a dosing strategy for enoxaparin in obese patients: 96
GREENBLATT, D.J. *see* OLUBODUN, J.O.
GREGOOR, P.J.H.S. *see* HESSELINK, D.A.
GRENZ, A. *see* FREUDENTHALER, S.
GUILLARD, O. *see* ASTUDILLO, L.
GUPTA, S.K., GLUE, P., JACOBS, S., BELLE, D. & AFFRIME, M. Single-dose pharmacokinetics and tolerability of pegylated interferon-α2b in young and elderly healthy subjects: 131
GUSTAFSSON, L.L. *see* HELLMAN, K.
GUSTAFSSON, L.L. *see* HERRLIN, K.
GUSTORFF, B. *see* SYCHA, T.

HÄRTTER, S., NORDMARK, A., ROSE, D.-M., BERTILSSON, L., TYBRING, G. & LAINE, K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity: 679
HAAS, C.S. *see* RENDERS, L.
HACKETT, L.P. *see* ALJAZAF, K.
HACKETT, L.P. *see* ISBISTER, G.K.
HAEFELI, W.E. *see* RENGELSHAUSEN, J.
HALE, T.W. *see* ALJAZAF, K.
HANSEN, K.T. *see* BIDSTRUP, T.B.
HARA, K. *see* IWASA, T.
HARDER, S. *see* GRAFF, J.
HARDER, S. *see* TOENNES, S.W.
HARMATZ, J.S. *see* OLUBODUN, J.O.
HARRIS, A. *see* CALLIES, S.
HARTMANN, P.E. *see* ALJAZAF, K.
HASCHKE, M. *see* PFRUNDER, A.
HAWKEY, C.J. *see* JAMES, M.W.
HAYCOX, A. *see* KUMANA, C.R.
HELLMAN, K., ROOS, E., ÖSTERLUND, A., WAHLBERG, A., GUSTAFSSON, L.L., BERTILSSON, L. & FREDRIKSON, S. Interferon-β treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity: 337

© 2003 Blackwell Publishing Ltd

HELMINEN, A. *see* ANTTILA, M.
HELMS, P.J. *see* EKINS-DAUKES, S.
HEMPEL, G., REINHARDT, D., CREUTZIG, U. & BOOS, J. Population pharmacokinetics of liposomal daunorubicin in children: 370
HERRLIN, K., YASUI-FURUKORI, N., TYBRING, G., WIDÉN, J., GUSTAFSSON, L.L. & BERTILSSON, L. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes: 415
HESSE, L.M. *see* OLUBODUN, J.O.
HESSELINK, D.A., NGYUEN, H., WABBIJN, M., GREGOOR, P.J.H.S., STEYERBERG, E.W., VAN RIEMSDIJK, I.C., WEIMAR, W. & VAN GELDER, T. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids: 327
HEUSTERSPREUTE, M. *see* ALLABI, A.C.
HORNUNG, C. *see* YAN, F.-X.
HORSMANS, Y. *see* ALLABI, A.C.
HOUGHTON, J.E. *see* SRI RANGANATHAN, S.
HUANG, M.Y. *see* BELLDINA, E.B.

IHNEN, M.A. *see* YAN, F.-X.
ILETT, K.F. *see* ALJAZAF, K.
Indices for Volume 56: 699
IQBAL, M.Z. *see* SHIRAN, M.R.
ISBISTER, G.K., HACKETT, L.P., DAWSON, A.H., WHYTE, I.M. & SMITH, A.J. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity: 441
ISHIBASHI, T., YANO, Y. & OGUMA, T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients: 205
ISHIZAKI, T. *see* IWASA, T.
ITOH, S. *see* NAKAGAWA, T.
IWASA, T., SANO, H., SUGIURA, A., UCHIYAMA, N., HARA, K., OKOCHI, H., NAKAGAWA, K., YASUMORI, T. & ISHIZAKI, T. An *in vitro* interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug: 537

JACKSON, C.M. *see* LEE, D.K.C.
JACKSON, C.M. *see* SIMS, E.J.
JACKSON, S.H.D. *see* MOORE, A.
JACOBS, S. *see* GUPTA, S.K.
JAMES, M.W. & HAWKEY, C.J. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract: 146
JEMAL, M. *see* LIAO, W.-C.
JICK, H. *see* KAYE, J.A.
JICK, S.S. *see* YANG, C.-C.
JOLLIET, P. *see* DAILLY, E.
JONES, A.L. *see* FLANAGAN, R.J.
JONSSON, E.N. *see* ZINGMARK, P.-H.
JURONEN, E. *see* YAN, F.-X.

KALITYNSKI, R. *see* DAWIDOWICZ, A.L.
KALMEIJER, M.D. *see* DUIJVESTIJN, Y.C.M.
KAMALI, F. Introduction to Drug Metabolism (Third Edition): 345
KARLSSON, M.O. *see* KERBUSCH, T.
KARLSSON, M.O. *see* ZINGMARK, P.-H.
KAUERT, G.F. *see* TOENNES, S.W.
KAYE, J.A., BRADBURY, B.D. & JICK, H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study: 569
KENDALL, M.J. Drugs Handbook 2003: 579
KERBUSCH, T., WÄHLBY, U., MILLIGAN, P.A. & KARLSSON, M.O. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, *CYP2D6* genotype and formulation-dependent bioavailability: 639
KINIRONS, M.T. *see* BROADHURST, C.
KIRCHMAIER, C.M. *see* GRAFF, J.
KISHINO, S. *see* NAKAGAWA, T.
KLINKHARDT, U. *see* GRAFF, J.
KNOWLES, S.R. *see* PHILLIPS, E.J.
KOKWARO, G.O. *see* OGUTU, B.R.
KOKWARO, G.O. *see* THOMSON, A.H.
KOKWARO, G.O., OGUTU, B.R., MUCHOHI, S.N., OTIENO, G.O. & NEWTON, C.R.J.C. Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions: 453
KOU, M. *see* KUMANA, C.R.
KRISHNAMOORTHY, R. *see* ADITHAN, C.
KRISTENSEN, J.H. *see* ALJAZAF, K.
KUMANA, C.R., TONG, M.K.L., LI, C.-S., LAUDER, I.J., LEE, J.S.K., KOU, M., WALLEY, T., HAYCOX, A. & CHAN, T.M. Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin: 670
KUNZENDORF, U. *see* RENDERS, L.

LABIRIS, N.R. & DOLOVICH, M.B. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications: 588
LABIRIS, N.R. & DOLOVICH, M.B. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications: 600
LAGUNDOYE, O. *see* SHIRAN, M.R.
LAIGHT, D.W. *see* FAYERS, K.E.
LAINE, K. *see* HÄRTTER, S.
LAINE, K. *see* PALOVAARA, S.
LAING, W.J. *see* LANGFORD, N.J.
LANGFORD, N.J., GOOD, A.M., LAING, W.J. & BATEMAN, D.N. Quinine intoxications reported to the Scottish Poisons Information Bureau 1997–2002: a continuing problem: 576
LANGUB, M.C. *see* YAN, F.-X.
LAUDER, I.J. *see* KUMANA, C.R.
LEE, D.K.C. *see* CURRIE, G.P.
LEE, D.K.C., JACKSON, C.M., CURRIE, G.P., COCKBURN, W.J. & LIPWORTH, B.J. Comparison of combination inhalers *vs* inhaled corticosteroids alone in moderate persistent asthma: 494
LEE, E.J.D. *see* BALRAM, C.
LEE, J.S.K. *see* KUMANA, C.R.
LEHR, S. *see* SYCHA, T.
LENNARD, M.S. *see* SHIRAN, M.R.
LEWITH, G. *see* BRIEN, S.
LI, C.-S. *see* KUMANA, C.R.
LIAO, W.-C., VESTERQVIST, O., DELANEY, C., JEMAL, M., FERREIRA, I., FORD, N., SWANSON, B. & UDERMAN, H. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects: 395
LIEBELT, J. *see* RENDERS, L.
LIMA, J.J. *see* CURRIE, G.P.
LIPWORTH, B.J. *see* CURRIE, G.P.
LIPWORTH, B.J. *see* LEE, D.K.C.
LIPWORTH, B.J. *see* SIMS, E.J.
LÖTSCH, J. *see* SKARKE, C.
LOGAN, R.P.H. *see* GODDARD, A.F.
LO-GUIDICE, J.-M. *see* ALLORGE, D.
LUDWIG, J. *see* RENGELSHAUSEN, J.
LYDEN, P. *see* ZINGMARK, P.-H.
LYONS, D. *see* MOORE, A.

MA, B. *see* PRUEKSARITANONT, T.
MACDONALD, T. *see* PATTERSON, D.
MAMDANI, M.M. *see* RAY, J.G.
MANGONI, A.A. *see* MOORE, A.
MANT, T.G.K. *see* DOWNHAM, M.R.
MATSUBARA, Y. *see* OHNUMA, T.
MAXWELL, S. *see* MUCKLOW, J.
MCINNES, G. *see* PATTERSON, D.
MCLACHLAN, A.J. *see* SASONGKO, L.
MCLAY, J.S. *see* EKINS-DAUKES, S.
MELAC, M. *see* PUROHIT, A.
MICCO, P.D. *see* SASSO, E.C.
MIKUS, G. *see* RENGELSHAUSEN, J.
MILLIGAN, P.A. *see* KERBUSCH, T.

MITOULAS, L.R. *see* ALJAZAF, K.
MIYAZAKI, K. *see* NAKAGAWA, T.
MÖRIKE, K. *see* FREUDENTHALER, S.
MOGHADAMNIA, A.A., ROSTAMI-HODJEGAN, A., ABDUL-MANAP, R., WRIGHT, C.E., MORICE, A.H. & TUCKER, G.T. Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan *vs.* dextrorphan using quinidine inhibition: 57
MOHAMMED, S. *see* THOMSON, A.H.
MOORE, A., MANGONI, A.A., LYONS, D. & JACKSON, S.H.D. The cardiovascular system in the ageing patient: 254
MORICE, A.H. *see* MOGHADAMNIA, A.A.
MUCHOHI, S.N. *see* KOKWARO, G.O.
MUCHOHI, S.N. *see* OGUTU, B.R.
MUCHOHI, S.N. *see* THOMSON, A.H.
MUCKLOW, J., BABER, N., MAXWELL, S. & PIRMOHAMED, M. The BPS web site for Continuing Professional Development in Clinical Pharmacology and Therapeutics: 349

NAKAGAWA, K. *see* IWASA, T.
NAKAGAWA, T., KISHINO, S., ITOH, S., SUGAWARA, M. & MIYAZAKI, K. Differential binding of disopyramide and warfarin enantiomers to human α_1-acid glycoprotein variants: 664
NEUVONEN, M. *see* NIEMI, M.
NEUVONEN, P.J. *see* NIEMI, M.
NEWTON, C.R.J.C. *see* KOKWARO, G.O.
NEWTON, C.R.J.C. *see* OGUTU, B.R.
NGYUEN, H. *see* HESSELINK, D.A.
NIEMI, M., BACKMAN, J.T., NEUVONEN, M. & NEUVONEN, P.J. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects: 427
NIESS, C. *see* TOENNES, S.W.
NIGLIO, A. *see* SASSO, E.C.
NORDMARK, A. *see* HÄRTTER, S.

ÖSTERLUND, A. *see* HELLMAN, K.
OBERBARNSCHEIDT, M. *see* RENDERS, L.
OCHS, H.R. *see* OLUBODUN, J.O.
ODERGREN, T. *see* ZINGMARK, P.-H.
OGUMA, T. *see* ISHIBASHI, T.
OGUTU, B.R. *see* KOKWARO, G.O.
OGUTU, B.R., NEWTON, C.R.J.C., MUCHOHI, S.N., OTIENO, G.O., EDWARDS, G., WATKINS, W.M. & KOKWARO, G.O. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus: 112
OHNUMA, T., SHIBATA, N., MATSUBARA, Y. & ARAI, H. Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6: 315
OKOCHI, H. *see* IWASA, T.
OLUBODUN, J.O., OCHS, H.R., VON MOLTKE, L.L., ROUBENOFF, R., HESSE, L.M., HARMATZ, J.S., SHADER, R.I. & GREENBLATT, D.J. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men: 297
OSSWALD, H. *see* FREUDENTHALER, S.
OTIENO, G.O. *see* KOKWARO, G.O.
OTIENO, G.O. *see* OGUTU, B.R.

PALOVAARA, S., TYBRING, G. & LAINE, K. The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects: 232
PANNIER, M. *see* DAILLY, E.
PARKS, V. *see* FERRON, G.M.
PASSIER, A.L.M. *see* DUIJVESTIJN, Y.C.M.
PATAT, A. *see* FERRON, G.M.
PATTERSON, D., WEBSTER, J., MCINNES, G., BRADY, A. & MACDONALD, T. The effects of KT3-671, a new angiotensin II (AT 1) receptor blocker in mild to moderate hypertension: 513
PAULI, G. *see* PUROHIT, A.
PENTTILÄ, J. *see* ANTTILA, M.
PFRUNDER, A., SCHIESSER, M., GERBER, S., HASCHKE, M., BITZER, J. & DREWE, J. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial: 683
PHILLIPS, E.J., KNOWLES, S.R. & SHEAR, N.H. Serum sickness-like reaction associated with clopidogrel: 583
PIRMOHAMED, M. *see* MUCKLOW, J.
POHLE, T. & DOMSCHKE, W. Gastric function measurements in drug development: 156
PONS, G. *see* CAZALI, N.
PRICE, A.B. Pathology of drug-associated gastrointestinal disease: 477
PRITCHARD, D. *see* BABER, N.
Proceedings of the Dutch Society for Clinical Pharmacology and Biopharmacy, 10 October 2003: 465
Proceedings of the London Hypertension Society 20 May 2003: 240
PRUEKSARITANONT, T., MA, B. & YU, N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6: 120
PUROHIT, A., MELAC, M., PAULI, G. & FROSSARD, N. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin: 388

RAMPTON, D.S. *see* CARTY, E.
RAY, J.G. & MAMDANI, M.M. Statins and the risk of idiopathic venous thromboembolism: 460
RAYENS, M.K. *see* YAN, F.-X.
REINHARDT, D. *see* HEMPEL, G.
RENDERS, L., HAAS, C.S., LIEBELT, J., OBERBARNSCHEIDT, M., SCHÖCKLMANN, H.O. & KUNZENDORF, U. Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients: 214
RENGELSHAUSEN, J., GÖGGELMANN, C., BURHENNE, J., RIEDEL, K.-D., LUDWIG, J., WEISS, J., MIKUS, G., WALTER-SACK, I. & HAEFELI, W.E. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction: 32
RETOUT, S. *see* BRUNO, R.
REY, E. *see* CAZALI, N.
RICHARDS, J.P. *see* DOWNHAM, M.R.
RIEDEL, K.-D. *see* RENGELSHAUSEN, J.
RIGAL, F. *see* ASTUDILLO, L.
ROLAN, P. *see* FERRON, G.M.
ROOS, E. *see* HELLMAN, K.
ROSE, D.-M. *see* HÄRTTER, S.
ROSEMARY, J. *see* ADITHAN, C.
ROSTAMI-HODJEGAN, A. *see* MOGHADAMNIA, A.A.
ROSTAMI-HODJEGAN, A. *see* SHIRAN, M.R.
ROSTAMI-HODJEGAN, A. *see* WILSON, Z.E.
ROSUL, A. *see* DOWNHAM, M.R.
ROUBENOFF, R. *see* OLUBODUN, J.O.
ROUTLEDGE, P.A. *see* SRI RANGANATHAN, S.
RUSHTON, A. *see* DOWNHAM, M.R.

SAILLER, L. *see* ASTUDILLO, L.
SANDERINK, G.-J. *see* BRUNO, R.
SANO, H. *see* IWASA, T.
SASONGKO, L., WILLIAMS, K.M., DAY, R.O. & MCLACHLAN, A.J. Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques: 551
SASSO, E.C., CARBONARA, O., MICCO, P.D., COPPOLA, L., TORELLA, R. & NIGLIO, A. A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy: 238
SATHIRAKUL, K., CHAN, C., TENG, L.,

© 2003 Blackwell Publishing Ltd

BERGSTROM, R.F., YEO, K.P. & WISE, S.D. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects: 184
SCHACTER, M. Principles of Clinical Pharmacology: 579
SCHEININ, H. *see* ANTTILA, M.
SCHELLENS, J.H. *see* CALLIES, S.
SCHIESSER, M. *see* PFRUNDER, A.
SCHMETTERER, L. *see* SYCHA, T.
SCHMIDT, H. *see* SKARKE, C.
SCHMIDT, T. *see* FREUDENTHALER, S.
SCHMITZ, G. & TORZEWSKI, M. HMG-Co reductase inhibitors: 458
SCHNEIDER, J.A. *see* BELLDINA, E.B.
SCHÖCKLMANN, H.O. *see* RENDERS, L.
SCHRAMM, M. *see* TOENNES, S.W.
SEIVEWRIGHT, N. *see* SHIRAN, M.R.
SELZER, T. *see* FREUDENTHALER, S.
SHADER, R.I. *see* OLUBODUN, J.O.
SHARABI, A., COHEN, E., SULKES, J. & GARTY, M. Replacement therapy for vitamin B12 deficiency: comparison between the sublingual and oral route: 635
SHARMA, A. *see* BALRAM, C.
SHARP, H.L. *see* DOWNHAM, M.R.
SHASHINDRAN, C.H. *see* ADITHAN, C.
SHAW, K.M. *see* FAYERS, K.E.
SHEAR, N.H. *see* PHILLIPS, E.J.
SHENFIELD, G. Clinical Pharmacology: 694
SHIBATA, N. *see* OHNUMA, T.
SHIRAN, M.R., CHOWDRY, J., ROSTAMI-HODJEGAN, A., ELLIS, S.W., LENNARD, M.S., IQBAL, M.Z., LAGUNDOYE, O., SEIVEWRIGHT, N. & TUCKER, G.T. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment: 220
SHUM, B., DUFFULL, S.B., TAYLOR, P.J. & TETT, S.E. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil: 188
SIDELMANN, U.G. *see* BIDSTRUP, T.B.
SIMPSON, C.R. *see* EKINS-DAUKES, S.
SIMS, E.J., JACKSON, C.M. & LIPWORTH, B.J. Add-on therapy with montelukast or formoterol in patients with the glycine-16 β2-receptor genotype: 104
SIVATHASAN, C. *see* BALRAM, C.
SJÖSTRÖM, L. *see* DOWNHAM, M.R.
SKARKE, C., SCHMIDT, H., GEISSLINGER, G., DARIMONT, J. & LÖTSCH, J. Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome: 228
SMALE, S. & BJARNASON, I. Determining small bowel integrity following drug treatment: 284
SMIERS, F. *see* DUIJVESTIJN, Y.C.M.
SMITH, A.J. *see* ISBISTER, G.K.
SRI RANGANATHAN, S., HOUGHTON, J.E., DAVIES, D.P. & ROUTLEDGE, P.A. The involvement of nurses in reporting suspected adverse drug reactions: experience with the meningococcal vaccination scheme: 658
STENBACK, S. *see* CURRIE, G.P.
STEYERBERG, E.W. *see* HESSELINK, D.A.
SUARD, F. *see* ALLORGE, D.
SUGAWARA, M. *see* NAKAGAWA, T.
SUGIMOTO, K.-I. & FUJIMURA, A. Different effects of simvastatin and pravastatin on adrenal sensitivity to angiotensin II: 696
SUGIURA, A. *see* IWASA, T.
SULKES, J. *see* SHARABI, A.
SWANSON, B. *see* LIAO, W.-C.
SWIFT, C.G. The clinical pharmacology of ageing: 249
SYCHA, T., GUSTORFF, B., LEHR, S., TANEW, A., EICHLERL, H.-G. & SCHMETTERER, L. A simple pain model for the evaluation of analgesic effects of NSAIDs in healthy subjects: 165
SYLVESTER, J.E. *see* CURRIE, G.P.

TALLEY, N.J. Evaluation of drug treatment in irritable bowel syndrome: 362
TANEW, A. *see* SYCHA, T.
TAYLOR, M.W. *see* EKINS-DAUKES, S.
TAYLOR, P.J. *see* SHUM, B.
TENG, L. *see* SATHIRAKUL, K.
TESTA, M.A. *see* YANG, C.-C.
TETT, S.E. *see* SHUM, B.
THOMAS, S.H.L. *see* EL-ERAKY, H.
THOMSEN, M.S. *see* BIDSTRUP, T.B.
THOMSON, A.H., KOKWARO, G.O., MUCHOHI, S.N., ENGLISH, M., MOHAMMED, S. & EDWARDS, G. Population pharmacokinetics of intramuscular gentamicin administered to young infants with suspected severe sepsis in Kenya: 25
TOENNES, S.W., HARDER, S., SCHRAMM, M., NIESS, C. & KAUERT, G.F. Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves: 125
TOMLINSON, H.S., CORLETT, S.A. & CHRYSTYN, H. Dose–response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation: 225
TONG, M.K.L. *see* KUMANA, C.R.
TOOLEY, A. *see* WILSON, Z.E.
TORELLA, R. *see* SASSO, E.C.
TORZEWSKI, M. *see* SCHMITZ, G.
TRACY, T.S. *see* BELLDINA, E.B.
TRAN, A. *see* CAZALI, N.
TRELUYER, J.M. *see* CAZALI, N.
TROY, S.M. *see* FERRON, G.M.
TUCKER, G.T. *see* MOGHADAMNIA, A.A.
TUCKER, G.T. *see* SHIRAN, M.R.
TUCKER, G.T. *see* WILSON, Z.E.
TYBRING, G. *see* HÄRTTER, S.
TYBRING, G. *see* HERRLIN, K.
TYBRING, G. *see* PALOVAARA, S.

UCHIYAMA, N. *see* IWASA, T.
UDERMAN, H. *see* LIAO, W.-C.

VAN GELDER, T. *see* HESSELINK, D.A.
VAN RIEMSDIJK, I.C. *see* HESSELINK, D.A.
VASEY, P. *see* CALLIES, S.
VASU, S. *see* ADITHAN, C.
VESTERQVIST, O. *see* LIAO, W.-C.
VEYRAT-FOLLET, C. *see* BRUNO, R.
VINCENT, J. *see* CAZALI, N.
VIVIER, N. *see* BRUNO, R.
VON MOLTKE, L.L. *see* OLUBODUN, J.O.
VOŽEH, S. Is the increasing use of evidence-based pharmacotherapy causing the renaissance of complementary medicine?: 292
VUORILEHTO, L. *see* ANTTILA, M.

WÄHLBY, U. *see* KERBUSCH, T.
WABBIJN, M. *see* HESSELINK, D.A.
WAGG, A. *see* BROADHURST, C.
WAHLBERG, A. *see* HELLMAN, K.
WALKER, M.M. & WHITTLE, B.J.R. British Journal of Clinical Pharmacology review series Clinical research methods in gastroenterology: 143
WALKER, M.M. Biopsy assessment of drug efficacy in the gastrointestinal tract: 483
WALLEY, T. *see* KUMANA, C.R.
WALTER-SACK, I. *see* RENGELSHAUSEN, J.
WATKINS, W.M. *see* OGUTU, B.R.
WEBSTER, J. *see* PATTERSON, D.
WEDLUND, P.J. *see* YAN, F.-X.
WEIMAR, W. *see* HESSELINK, D.A.
WEISS, J. *see* RENGELSHAUSEN, J.
WESTRUP, D. *see* GRAFF, J.
WHITTLE, B.J.R. *see* WALKER, M.M.
WHYTE, I.M. *see* ISBISTER, G.K.
WIDÉN, J. *see* HERRLIN, K.
WILLIAMS, K.M. *see* SASONGKO, L.
WILSON, K.C.M. *see* BROADHURST, C.
WILSON, Z.E., ROSTAMI-HODJEGAN, A., BURN, J.L., TOOLEY, A., BOYLE, J., ELLIS, S.W. & TUCKER, G.T. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver: 433
WISE, S.D. *see* SATHIRAKUL, K.
WOOD, R.J. *see* CAMIDGE, D.R.

WRIGHT, C.E. *see* MOGHADAMNIA, A.A.

YAN, F.-X., LANGUB, M.C., IHNEN, M.A., HORNUNG, C., JURONEN, E., RAYENS, M.K., CAI, W.-M., WEDLUND, P.J. & FANTI, P. CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy: 68

YANG, C.-C. & JICK, S.S. Author's response to letter from Ray *et al.*: 461

YANG, C.-C., JICK, S.S. & TESTA, M.A. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics: 84

YANO, Y. *see* ISHIBASHI, T.

YASUI-FURUKORI, N. *see* HERRLIN, K.

YASUMORI, T. *see* IWASA, T.

YEO, K.P. *see* SATHIRAKUL, K.

YU, N. *see* PRUEKSARITANONT, T.

YUSUFI, B. *see* FLANAGAN, R.J.

ZINGMARK, P.-H., EKBLOM, M., ODERGREN, T., ASHWOOD, T., LYDEN, P., KARLSSON, M.O. & JONSSON, E.N. Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients: 173

© 2003 Blackwell Publishing Ltd

SUBJECT INDEX

This index was compiled from the keywords
(P = Proceedings, S = Supplement)

α_1-acid glycoprotein, 664
5-hydroxytryptamine 1B/1D receptor agonist, 537
active metabolite, 57
acute coronary syndromes, 407
adenosine monophosphate, 104
administration, 588, 600
adverse drug reaction, 658
adverse effect, 415
adverse reactions, 249
aerosol, 588, 600
ageing, 249, 254, 297
allergy, 388
alosetron, 362
angina, 407
angiotensin conjugate vaccines, 505
angiotensin converting enzyme, 395
angiotensin II, 3, 378, 513
antibiotics, 92
anticancer drug, 205
antidepressant, 415, 441
antidepressants, 362
antiepileptics, 39
antiepileptic agents, 526
antihistamines, 501
anti-histamine, 388
antimigraine agent, 537
antioxidants, 620
antipsychotic drugs, 569
antispasmodics, 362
arteries, 254
Asian population, 78
aspirin, 321
asthma, 104, 422, 494
asthma therapy, 11
AT_1 antagonist, 3

β_2-agonists, 104
Belgium, 653
Benin, 653
bioavailability, 32, 691
biopsy, 483
blood pressure, 395, 513
bound drug, 545
bronchial hyperresponsiveness, 422
budesonide, 494
bupropion, 451
burns, 629

caffeine, 679
capsaicin, 501
carbamazepine, 526
cardiac repolarization, 198
cathine (d-norpseudoephedrine), 125
cathinone, 125
ceftazidime, 629
cerivastatin, 214
chest pain, 451
children, 92, 453
citalopram, 415
clarithromycin, 32
clearance, 205
clinical pharmacology, 249
clinical trials, 249
cobalamin deficiency, 635
collagenous colitis, 477
combination inhalers, 494
comorbidity, 84
complementary medicine, 292
corticosteroids, 327
cost-effectiveness analysis, 670
cough, 501
Crohn's disease, 351
cyclosporin A, 78
cyclosporin Neoral®, 670
CYP1A2, 184, 341, 679
CYP2C19, 232, 337, 415, 653
CYP2C19 polymorphism, 331
CYP2C8, 120, 306, 653
CYP2D6, 57, 120, 220, 315, 337, 415, 639
CYP3A4, 78, 120, 306
CYP3A5, 120
cystinosis, 520
cytochromes, 683
cytochrome P450, 214, 232, 341, 433
cytochrome P450 inhibition, 306
cytochrome P-450, 337

darifenacin, 639
delirium, 261
dexmedetomidine, 691
dextromethorphan, 220
diaphragm disease, 477
digoxin, 32
diltiazem, 334, 670
disopyramide, 664
dosage conservation, 670
dose–effect curves, 3
dose–response, 225
double-blind randomized trial, 670
drug, 483
drug development, 156, 273, 292
drug effects, 683
drug interaction, 39, 427, 526
drug interactions, 32, 327, 526
drug regulation, 292
drug treatment, 273
drug utilization, 569
drug-associated gastrointestinal pathology, 477
drugs, 284

EGG, 156
elderly, 131, 261
enantiomers, 415
endothelial dysfunction, 620
enoxaparin, 96
epidemiology, 613
epitopic suppression, 505
erythropoietin, 378
ethinyloestradiol, 232
ethnicity, 78
evidence-based medicine, 292

fexofenadine, 501
fluconazole, 551
fluticasone, 11, 494
formoterol, 104, 494
fosphenytoin, 112
free drug, 545
furosemide, 378

gastric function, 156
gastrointestinal, 483
gastrointestinal tract, 146
gastroparesis, 156
gender, 68
gene duplication, 315
General Practice Research Database, 84
genetics, 104
genotype, 68, 415, 653
genotyping, 331
gentamicin, 25
Gilbert's syndrome, 228
glucuronidation, 39
GORD, 156
GPIIb/IIIa receptor, 321

haemorrhage, 407
haloperidol, 315
healthy volunteers, 378
Helicobacter pylori, 273
heparin, 321
high salt-diet, 378
histopathology, 483
homeopathy, 562
human, 32, 551
human CSF, 545
human liver microsomes, 306
human milk, 18
human monoamine oxidase (MAO), 537
hydroxymethylglutaryl-CoA reductase inhibitors, 84
hyperlipidaemia, 214
hypertension, 505, 513

immunohistochemistry, 68
in silico ADME, 433
Indian, 331
induction, 39
infant dose, 18
infants, 25
inflammation, 11, 494
inflammatory bowel disease, 351
inhalation, 225, 588, 600
inotropes, 254
interaction, 321, 683
interethnic difference, 537
interferon α2b, 131
interferon-β, 337

intestinal inflammation, 284
intestinal permeability, 284
intestinal toxicity, 284
intramuscular injection, 25
intraventricular haemorrhage, 581
irritable bowel syndrome, 362

ketoconazole, 334
khat, 125
kidney transplantation, 327

leukotriene antagonists, 104
leukotriene receptor antagonist, 422
levonorgestrel, 232
lipid-lowering drugs, 84
liposomal daunorubicin, 370
liver microsomes, 433
logistic regression, 173
long QT syndrome, 198
low salt-diet, 378
lung, 588, 600
lymphocytic colitis, 477

M : P ratio, 18
malaria, 112, 453
mania, 415
Mdr1 gene, 78
melatonin, 679
meningococcal group C conjugate vaccine, 658
mephenytoin, 415
metabolic ratio, 415
metabolism, 415
metabolites, 415
methacholine challenge, 494
methadone maintenance treatment, 220
microdialysis, 551
milk production, 18
moclobemide, 441
modelling, 96
montelukast, 104
morphine, 228
multiple sclerosis, 337
mycophenolate, 188
myocardial infarction, 407

nateglinide, 427
nedaplatin, 205
neutral endopeptidase, 395
newborn, 581
nitrate tolerance, 620
nitric oxide, 620
nonlinear mixed effects models, 173
NONMEM, 96
nonpharmacological, 261
nonsteroidal anti-inflammatory drugs pseudomembranous colitis, 477
norephedrine (phenylpropanolamine), 125
NSAIDs, 146, 165, 284
nurses, 658

obesity, 96
oestradiol, 334
oestrogen metabolism, 334
off-label, 92
olanzapine, 184
omapatrilat, 395
omeprazole, 232
oral contraceptives, 232, 683
oral, 635
outcomes studies, 146
overdose, 441, 613
oxidative deamination, 537
oxidative stress, 620

paclitaxel, 46
paediatrics, 370
pain model, 165
pathogenesis, 249
pathophysiology, 261
pegylation, 131
P-glycoprotein modulator, 46
P-glycoprotein, 32, 78, 683
pharmacodynamic study, 165
pharmacodynamics, 3, 96, 395, 520
pharmacogenetics, 341
pharmacokinetics, 25, 78, 96, 112, 125, 131, 173, 184, 188, 228, 297, 327, 395, 415, 441, 453, 520, 551, 639, 683, 691
pharmacological, 261
pharmacological methods, 362
pharmacology clinical trials, 351
pharmacovigilance, 451
phenobarbital, 453
phenobarbitone, 39
phenotype, 415
phenotype–genotype discordance, 220
phenytoin, 112
pH-metry, 156
physiology, 249
placebo effect, 292
placebo, 292
plant alkaloids, 68
plasma concentration, 315
platinum, 205
poisoning, 576
policy, 249
polymorphism, 68, 104, 341
pooled analysis, 639
population analysis, 188
population pharmacokinetics, 46, 205, 370, 407, 629, 639
population pharmacokinetics–pharmacodynamics, 57
postmenopausal, 334
prediction of metabolic clearance, 433
prescribing, 92, 249
propofol, 545
proportional odds model, 173
pseudoephedrine, 18
pulmonary function, 494
pulmonary function tests, 501

quinine, 576

race, 184
randomized controlled trial, 562
RCT, 165
receptors, 513
recovery, 494
renal failure, 68
renal transplantation, 214
renin angiotensin aldosterone system, 3
renin-angiotensin system, 620

repaglinide, 306
research, 249
retigabine, 39
review, 588, 600
rhinitis, 388
rifampicin, 427
rizatriptan, 537

salbutamol, 494
salmeterol, 11, 494
Schild regression plot, 3
sedation, 173
selective serotonin reuptake inhibitors, 581
self-poisoning, 613
serotonin, 362, 441
sex, 198
simvastatin hydroxy acid, 120
simvastatin, 120
smoking cessation, 451
splicing mutation, 341
St John's wort, 683
status epilepticus, 112, 453
stereoisomerism, 415
stereoselective binding, 664
stroke, 173
sublingual, 635
suction blisters, 551
suicide, 613
Swedes, 415
sympathetic nervous system, 254

tacrolimus, 214, 327
Tamilian, 331
TCI, 545
tegaserod, 362
testosterone, 297
thioridazine, 569
tissue distribution, 551
torsade de pointes, 198
toxbase, 576
toxicity, 441
treatment refusal, 84
treatment, 261, 351

UK-148, 639, 993
ulcerative colitis, 351
ultramolecular, 562
United Kingdom, 613
urinary salbutamol, 225

validation, 205
variability in metabolism, 433
variant, 664
vasopeptidase inhibitor, 395
veins, 254
volunteer endoscopy, 146

warfarin, 664
weal and flare model, 388

yawning, 415
yellow card, 658
YM337, 321
young, 131

zolpidem, 297
Zosuquidar 3HCl, 46

© 2003 Blackwell Publishing Ltd